Abstract
The increasing administrative burden associated with conducting clinical trials is a threat to patient safety, independent academic clinical research, and access to affordable innovation. While the Clinical Trials Regulation1 —adopted by the European Parliament in 2014 to replace the Clinical Trials Directive2 (from 2001) and finally expected to become applicable in the course of 2020—will go some way in addressing bureaucracy overload, more action is needed. This article discusses the issues resulting from the exponential growth of regulatory and administrative requirements for the conduct of clinical studies and the impact this is having on researchers and patients. It also describes how the European Hematology Association (EHA) is coordinating a series of activities to advance potential solutions for these issues.
DOI
10.1097/hs9.0000000000000352
Publication Date
2020-01-01
Publication Title
HemaSphere
Volume
4
Issue
2
Publisher
Lippincott, Williams & Wilkins
ISSN
2572-9241
Embargo Period
2024-11-19
First Page
e352
Last Page
e352
Recommended Citation
Gribben, J., Macintyre, E., Sonneveld, P., Doorduijn, J., & et al. (2020) 'Reducing Bureaucracy in Clinical Research: A Call for Action', HemaSphere, 4(2), pp. e352-e352. Lippincott, Williams & Wilkins: Available at: https://doi.org/10.1097/hs9.0000000000000352
